btimesonline2h
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
STAT5h
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
USA Today18h
This FDA-approved drug promises a new way to treat schizophrenia
The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...
ENDPOINTS NEWS18h
End­points 11 win­ner Sea­port Ther­a­peu­tics: The Karuna team is back with an­oth­er big bet in neu­ro­science
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...
The Washington Post20h
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
Based largely on Cobenfy’s promise, Bristol Myers Squibb paid $14 billion to acquire the company that developed the drug, ...